A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.

@article{Sneller2012ARC,
  title={A randomized controlled trial of rituximab following failure of antiviral therapy for hepatitis C virus-associated cryoglobulinemic vasculitis.},
  author={Michael C Sneller and Zonghui Hu and Carol A Langford},
  journal={Arthritis and rheumatism},
  year={2012},
  volume={64 3},
  pages={835-42}
}
OBJECTIVE To perform a randomized controlled trial of rituximab in patients with hepatitis C virus (HCV)-associated mixed cryoglobulinemic vasculitis. METHODS We conducted a single-center, open-label, randomized controlled trial of rituximab (375 mg/ m(2) /week for 4 weeks) compared to the best available therapy (maintenance or increase in immunosuppressive therapy) for HCV-associated cryoglobulinemic vasculitis in patients in whom antiviral therapy had failed to induce remission. The primary… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
45 Citations
25 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 45 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 25 references

Similar Papers

Loading similar papers…